Breast Imaging

What Is the Best Imaging for Axillary Staging in DCIS with Microinvasion?

·
What Is the Best Imaging for Axillary Staging in DCIS with Microinvasion?

It’s late in the afternoon clinic, and you’re reviewing the pathology report for a 54-year-old patient’s recent stereotactic biopsy. The result is Ductal Carcinoma in Situ (DCIS), but with an important addition: “foci of microinvasion.” This finding shifts the clinical picture. While pure DCIS is non-invasive, microinvasion introduces a small but real risk of axillary lymph node involvement. Before the patient proceeds to surgery, the multidisciplinary team needs to evaluate the axilla. This article details the clinical workflow for this specific scenario: choosing the next imaging study for axillary evaluation in a patient with known DCIS with microinvasion. Based on the American College of Radiology (ACR) Appropriateness Criteria, the indicated study is an axillary ultrasound, which is rated Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for an adult patient with a new, biopsy-proven diagnosis of Ductal Carcinoma in Situ (DCIS) where microinvasion has been identified on the initial pathology. The clinical question is strictly about the next imaging step for axillary evaluation prior to definitive surgical treatment.

Inclusion Criteria:

  • Diagnosis: Biopsy-proven DCIS with microinvasion (DCIS-MI).
  • Timing: The patient is in the initial workup and treatment planning phase.
  • Clinical Question: Non-invasive imaging of the ipsilateral axilla is needed to assess for potential nodal metastasis.

Exclusion Criteria (These patients follow different guidelines):

  • Pure DCIS without Microinvasion: In cases of pure DCIS, the risk of nodal metastasis is exceedingly low, and preoperative axillary imaging is not routinely performed. This patient would fall under the Newly diagnosed DCIS. Initial imaging. scenario.
  • Invasive Ductal Carcinoma (IDC): If the biopsy shows frank invasive carcinoma (beyond microinvasion), the patient’s staging and treatment algorithm is different, often involving a more comprehensive staging workup depending on tumor size and characteristics.
  • Evaluation for Recurrence: This guidance does not apply to patients with a prior history of DCIS who are now being evaluated for a suspected local recurrence. Those patients follow separate surveillance or symptomatic workup pathways.

What Diagnoses Are You Working Up in This Scenario?

When ordering an imaging study for axillary evaluation in DCIS with microinvasion, the primary goal is to identify or exclude nodal metastases, which can significantly alter surgical management. The differential diagnosis for findings in the axilla includes several possibilities.

The most consequential diagnosis is axillary lymph node metastasis. The presence of microinvasion means that cancer cells have breached the basement membrane of the milk duct, gaining the potential to travel to regional lymph nodes. While the overall risk is low compared to frankly invasive cancer, identifying a metastatic node preoperatively allows for a targeted biopsy. A positive biopsy can change the planned surgical procedure from a sentinel lymph node biopsy (SLNB) to a more extensive axillary lymph node dissection (ALND) or guide neoadjuvant therapy decisions.

A more common finding is benign reactive lymphadenopathy. Lymph nodes can become enlarged and prominent due to a variety of non-malignant causes, including inflammation, infection, or even recent biopsy-related changes in the breast. Ultrasound can often distinguish these nodes from metastatic ones based on morphological features like a preserved fatty hilum, cortical thickness, and overall shape, but some overlap can exist.

Finally, the imaging may simply show normal axillary lymph nodes. A completely negative and unremarkable axillary ultrasound provides reassurance, though it does not eliminate the need for surgical staging. It confirms that the patient is a candidate for a standard sentinel lymph node biopsy at the time of their breast surgery, as microscopic, non-visible metastases can still be present.

Why Is Axillary Ultrasound the Recommended Study for This Presentation?

For a patient with DCIS with microinvasion requiring axillary evaluation, the ACR designates axillary ultrasound as Usually Appropriate. This recommendation is based on the modality’s excellent balance of diagnostic capability, safety, and accessibility for this specific clinical question.

The primary rationale is that ultrasound is highly effective at identifying morphologically suspicious lymph nodes. It provides high-resolution imaging of the nodal cortex, hilum, and overall shape. Features concerning for malignancy—such as cortical thickening, rounded shape, and loss of the fatty hilum—are well-visualized. If a suspicious node is identified, ultrasound provides the real-time guidance necessary to perform a fine-needle aspiration (FNA) or core needle biopsy for definitive pathologic diagnosis, all in the same session if needed.

Furthermore, axillary ultrasound is a safe and non-invasive procedure. It involves no ionizing radiation (0 mSv) and does not require intravenous contrast, avoiding potential allergic reactions or renal complications. This is a significant advantage over other cross-sectional imaging modalities.

Why are other studies rated lower for this scenario?

  • MRI breast without and with IV contrast is rated Usually not appropriate for this specific indication. While breast MRI is excellent for assessing the extent of disease within the breast, its performance for axillary staging is variable and it is generally less specific than targeted ultrasound. It is more costly, less available, and not the primary tool for this focused question.
  • FDG-PET/CT whole body is also rated Usually not appropriate. This powerful systemic staging tool is considered excessive for DCIS with microinvasion, which has a low pre-test probability of distant metastatic disease. FDG-PET/CT exposes the patient to significant ionizing radiation (10-30 mSv) and is reserved for staging more advanced breast cancers or investigating suspected distant metastases.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound will directly guide the next steps in the patient’s surgical and oncologic management. The workflow branches based on whether the findings are negative, positive, or indeterminate.

If the axillary ultrasound is negative:
If no morphologically suspicious lymph nodes are identified, the patient proceeds to the operating room for their planned breast surgery (lumpectomy or mastectomy) combined with a sentinel lymph node biopsy (SLNB). A negative preoperative ultrasound does not eliminate the need for SLNB, as it cannot detect microscopic disease. The SLNB remains the gold standard for surgically staging the axilla in this setting.

If the axillary ultrasound is positive (shows a suspicious node):
The next step is an ultrasound-guided biopsy of the most suspicious-appearing lymph node. This is typically done via fine-needle aspiration (FNA) or core needle biopsy.

  • If the node biopsy is positive for metastatic carcinoma, the patient is now considered node-positive. This upstages their disease and may alter the surgical plan. They may proceed directly to an axillary lymph node dissection (ALND) instead of an SLNB, or they may be considered for neoadjuvant (pre-surgical) systemic therapy.
  • If the node biopsy is negative, the patient typically still undergoes an SLNB at the time of surgery, as the biopsied node may not be the sentinel node, or the biopsy could have been a false negative.

If the axillary ultrasound is indeterminate:
When a lymph node has features that are not clearly benign or malignant, management depends on the degree of suspicion and institutional practice. This may involve a short-term follow-up ultrasound, proceeding directly to an ultrasound-guided biopsy, or proceeding with the standard SLNB at the time of surgery, with the surgeon aware of the indeterminate finding.

Pitfalls to Avoid (and When to Get Help)

When managing the axillary evaluation for DCIS with microinvasion, several common pitfalls can impact patient care.

First, avoid the assumption that a negative ultrasound rules out nodal disease. A normal-appearing axilla on ultrasound does not preclude the presence of micrometastases. Sentinel lymph node biopsy remains the standard of care for surgical staging.

Second, ensure the ultrasound examination is comprehensive. The radiologist should thoroughly evaluate all axillary levels (I, II, and III) as well as the infraclavicular and supraclavicular regions, as metastases can occasionally appear in atypical locations.

Third, be aware of the limitations of morphology. A reactive lymph node from a recent breast biopsy can sometimes mimic a malignant node. Pathologic confirmation of any suspicious node is crucial before committing a patient to a more aggressive surgical procedure like an axillary dissection.

If a patient presents with bulky, palpable, or matted axillary lymph nodes on physical exam, this represents a clinical red flag. Even before imaging, this finding suggests more advanced disease and warrants urgent escalation for tissue sampling and consideration by a multidisciplinary tumor board for potential neoadjuvant therapy.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to imaging DCIS, from initial diagnosis to surveillance, please consult the parent topic article. For additional resources to help guide your imaging decisions, see the tools below.

Frequently Asked Questions

Why not just go straight to sentinel node biopsy without preoperative imaging?

While sentinel lymph node biopsy (SLNB) is the surgical standard, preoperative axillary ultrasound serves a crucial role. If it identifies a positive lymph node that is then confirmed by biopsy, it can change the surgical plan, potentially allowing a patient to proceed directly to axillary lymph node dissection (ALND) and avoiding a second surgery. It helps stratify risk and plan the most efficient treatment pathway.

What features make a lymph node suspicious on ultrasound?

Suspicious features on ultrasound include a rounded (rather than oval) shape, loss of the central fatty hilum, diffuse or focal cortical thickening (often defined as >3 mm), and eccentric cortical thickening. The presence of any of these findings would typically prompt a recommendation for biopsy.

If the axillary ultrasound and subsequent biopsy are positive, is SLNB still necessary?

Generally, no. A biopsy-proven positive axillary node establishes N1 disease. Historically, this would lead directly to a full axillary lymph node dissection (ALND). More recently, clinical trials (like ACOSOG Z0011) have shown that for certain patients with limited nodal disease undergoing lumpectomy and whole-breast radiation, a full ALND may not be necessary. However, a positive preoperative biopsy does change the conversation from SLNB to either ALND or targeted axillary dissection.

Does this guidance change if the microinvasion was found on an MRI-guided biopsy?

No, the indication for axillary evaluation is based on the final pathologic finding of microinvasion, regardless of the imaging modality or biopsy technique used to obtain the tissue. The need to assess the axilla remains the same, and axillary ultrasound is still the appropriate first imaging step.

Is CT or PET/CT ever appropriate for staging DCIS with microinvasion?

For the initial staging of uncomplicated DCIS with microinvasion, CT and PET/CT are rated as *Usually not appropriate* by the ACR. The risk of distant metastatic disease is extremely low in this setting, and the radiation exposure from these studies is not justified. These modalities are reserved for staging more advanced invasive cancers, cases with high-volume axillary disease, or when there is clinical suspicion of distant metastases.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026